Helixmith Co. Ltd (084990.KQ) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · South Korea · ISIN KR7084990001

Price

3,675.00 KRW

Market cap

169.22 bn KRW

P/E (2025)

–

P/S (2025)

65.13

Dividend yield

0.00 %

Net margin

-16.74 %

Return on equity (ROE)

-0.31 %

Return on assets (ROA)

-0.30 %

Helixmith Co. Ltd financials

Fiscal year	2024	2025
Revenue	4.97 bn KRW	2.60 bn KRW
Gross profit	2.88 bn KRW	988.43 m KRW
Operating income	-18.13 bn KRW	-9.89 bn KRW
EBIT	-15.32 bn KRW	-454.38 m KRW
Net income	-15.47 bn KRW	-434.92 m KRW
Diluted EPS – continuing operations	-335.99 KRW	-9.45 KRW

Full history since 2010, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Helixmith Co. Ltd

Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological diseases. The company's pipeline products include VM206, a therapeutic cancer vaccine targeting HER2/neu positive breast or ovarian cancer; and VM501, a re-engineered form of interleukin 11 targeting chemotherapy-induced thrombocytopenia. Its clinical trials biologics comprise VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. The company was formerly known as ViroMed Co., Ltd. and changed its name to Helixmith Co., Ltd in April 2019. Helixmith Co., Ltd was incorporated in 1996 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.